Hepatic Resection Versus Transplantation for Hepatocellular Carcinoma

TLDR

Improving survival in HCC requires nonsurgical anti‑cancer therapies before or after surgery. The study compared 76 HCC patients undergoing subtotal hepatic resection with 105 patients receiving orthotopic liver transplantation under cyclosporine‑steroid therapy over a decade. Survival rates were similar between resection and transplantation overall, but transplantation yielded better outcomes in cirrhotic patients; recurrence remained high, and long‑term survivors were mainly early‑stage or fibrolamellar HCC.

Abstract

During the 10-year period (1980 to 1989), 76 patients with hepatocellular carcinoma (HCC) were treated by subtotal hepatic resection (HX) and 105 patients by orthotopic liver transplantation (TX) under cyclosporine-steroid therapy. Overall 1− to 5-year survival rates of the HX group were 71.1%, 55.0%, 47.2%, 37.2%, and 32.9%, respectively, and those of the TX group were 65.7%, 49.0%, 39.2%, 35.6%, and 35.6%, respectively. The survival rates after HX and after TX correlated well with pTNM stages and were similar in each stage between the two groups. However, when HCC was associated with cirrhosis of the liver, the survival rates after TX were significantly better than those after HX at each stage of pTNM classification. The tumor-recurrence rate was high both after HX (50%) and TX (43%), particularly in advanced stages of pTNM classification (60% or more). Twelve patients after HX and 13 patients after TX lived more than 5 years during this 10-year period. Fibrolamellar HCC and early stages of HCC were highly represented among the long-term survivors. Further improvement in survival rates depends on nonsurgical anti-cancer therapy before and/or after surgical removal of HCC.